WAYNE, Pa., July 21, 2016 /PRNewswire/ -- Bracket, a leading clinical trial technology and specialty services provider with expertise in Alzheimer's disease (AD), will present new data at the Alzheimer's Association International Conference (AAIC) held on July 24 – 28, 2016 in Toronto, Canada and exhibit at Booth 524.
The Conference will bring together international investigators, clinicians and care providers to discuss the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science. As AD clinical trials have become larger and more global, Bracket has worked to improve AD research Clinical Outcomes Assessments.
"Alzheimer's disease clinical trials are challenging. We continue to strive to improve study outcomes data quality with the ultimate goal of providing better treatment options to patients and caregivers alike," said Dr. David Miller, Clinical Vice President and Therapeutic Area Leader for Alzheimer's at Bracket. "Attending scientific forums like AAIC are essential to this goal."
Bracket will be presenting new data related to ongoing work in electronic clinical outcomes assessments (eCOA) and quality assurance for AD trials. This will include new research highlighting the need for rigorous, ongoing review of clinical interviews to ensure site ratings quality.
Early-to-market with a flexible platform for eCOA and with specialties in AD trial technology and services, Bracket uses an advanced tool, called the Rater Station, to effectively collect patient and caregiver data in clinical trials. The Company also offers Blinded Data Analytics and Quality Assurance programs that combine the statistical analysis of raw and derived data with rigorous clinical assessment and interpretation of the results to identify areas of concern.
To date, Bracket's eCOA experience for AD includes the evaluation of 5,000 subjects; completion of 45,000 unique scale administrations; recording of 14,000 subjects; and 25 unique clinical outcomes assessments.
"As an advocate of digitization in clinical trials for its ability to streamline data collection, improve patient engagement and deliver real ROI, we are proud to bring eCOA tools to AD research initiatives and look forward to attending AAIC to better understand how we may best assist the field to discover new treatments," said Jeff Kinell, CEO at Bracket.
To learn more about Bracket's eCOA tools for AD trials, visit www.bracketglobal.com.
Bracket, with seven offices and more than 500 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at www.bracketglobal.com.
The Alzheimer's Association International Conference (AAIC) is the world's largest forum for the dementia research community. International investigators, clinicians and care providers gather annually to share the latest study results, theories and discoveries that bring the world closer to breakthroughs in dementia science. Learn more about AAIC at www.alz.org/aaic.
Sagefrog Marketing Group on behalf of Bracket